CTOs on the Move

Aurinia Pharmaceuticals

www.auriniapharma.com

 
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.auriniapharma.com
  • 500 W Office Center Drive Suite 400
    Fort Washington, PA USA 19034
  • Phone: 250.708.4272

Executives

Name Title Contact Details
Darin Wilson
Senior Director, Enterprise IT Profile

Funding

Aurinia Pharmaceuticals raised $28.75M on 12/29/2016
Aurinia Pharmaceuticals raised $173.1M on 03/20/2017
Aurinia Pharmaceuticals raised $191.7M on 12/12/2019

Similar Companies

Genyous Life Sciences

Genyous Life Sciences is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.

AMIGENICS

AMIGENICS is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Singular Genomics

Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.